Course Overview
This content was accurate at the time of release, 26 December 2021. Accreditation for this course expired on 27 December 2022. If you would still like an activity completion certificate, send your request to [email protected].
This case study features expert discussion surrounding a real HCM patient and is designed to raise awareness about the frequency of atrial fibrillation in HCM patients and the challenges associated with managing atrial fibrillation symptoms. It assists clinicians in community practice or those with an interest in HCM management to:
- understand the underlying cause of atrial fibrillation in HCM patients
- provide appropriate pharmacotherapy management strategies for atrial fibrillation
- understand invasive therapy options for atrial fibrillation and their limitations in HCM patients
- know when referral to an HCM expert center is appropriate
This case study discussion is designed to be completed in 45 minutes.
Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors
Funding disclosure: This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi.
Learners may participate in this educational activity free of charge.
- Atrial fibrillation in patients with HCM: background
- Pharmacological treatment of atrial fibrillation symptoms in patients with HCM
- Invasive therapies for management of atrial fibrillation in patients with HCM
At the end of this case study, delegates should be able to:
- Recognize the signs of atrial fibrillation in patients with HCM and apply to a sample patient
- Explain complications that may arise as a result of atrial fibrillation in patients with HCM
- List strategies for treatment of atrial fibrillation in patients with HCM and utilize these on an example patient
Accreditation for this course has expired. You may view the program, but CME/ CE is no longer available and no certificate will be issued.
Faculty disclosure:
Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, has received financial compensation for consulting for Cytokinetics and Imbria, and received research grants from Takeda and iRhythm.
Dr Anjali Tiku Owens, MD, Medical Director of the Advanced Heart Failure and Transplant Cardiology, Penn Center for Inherited Cardiovascular Disease/ University of Pennsylvania, received financial compensation for consulting for MyoKardia/BMS and Cytokinetics.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.